State Board of Administration of Florida Retirement System lowered its position in Qiagen (NYSE:QGEN – Get Rating) by 4.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 277,385 shares of the company’s stock after selling 12,937 shares during the quarter. State Board of Administration of Florida Retirement System owned approximately 0.12% of Qiagen worth $13,093,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CWM LLC lifted its stake in Qiagen by 446.2% in the first quarter. CWM LLC now owns 579 shares of the company’s stock valued at $28,000 after buying an additional 473 shares during the last quarter. Captrust Financial Advisors lifted its stake in Qiagen by 23.1% in the first quarter. Captrust Financial Advisors now owns 1,232 shares of the company’s stock valued at $60,000 after buying an additional 231 shares during the last quarter. KBC Group NV lifted its stake in Qiagen by 41.6% in the first quarter. KBC Group NV now owns 3,426 shares of the company’s stock valued at $168,000 after buying an additional 1,006 shares during the last quarter. Balentine LLC purchased a new stake in Qiagen in the first quarter valued at approximately $211,000. Finally, Delphia USA Inc. purchased a new stake in Qiagen in the first quarter valued at approximately $230,000. Hedge funds and other institutional investors own 55.65% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on the company. Citigroup reduced their price objective on Qiagen from $62.00 to $55.00 and set a “buy” rating for the company in a research note on Wednesday. Morgan Stanley began coverage on Qiagen in a research note on Tuesday, October 18th. They set an “equal weight” rating for the company. StockNews.com began coverage on Qiagen in a research note on Wednesday, October 12th. They set a “buy” rating for the company. Finally, Oddo Bhf cut Qiagen from an “outperform” rating to a “neutral” rating in a research note on Monday, October 10th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Qiagen has a consensus rating of “Hold” and an average price target of $54.67.
Qiagen Trading Up 0.5 %
Qiagen Company Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
- Get a free copy of the StockNews.com research report on Qiagen (QGEN)
- Is Triple-Digit Growth Ahead For Digital Ad Platform Trade Desk?
- EV Maker Lucid Falls On Declining Orders, Rivian Up On Guidance
- Goodyear Tire & Rubber Stock is Becoming a Mighty Good Bargain
- DoorDash Outperforms Despite Losses – Is It Time To Buy?
- Analysts Rate DraftKings a Moderate Buy As Growth Slows
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.